Compare Stocks: TRLV, BLTE, LNTH, and AMRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$18.42 +1.5%	$17.33	$9.20 ▼ $19.26	$5.80B	1.27	1.87 million shs	1.62 million shs
BLTE Belite Bio	$163.21 +0.3%	$152.97	$60.00 ▼ $200.00	$6.53B	-1.22	186,143 shs	180,493 shs
LNTH Lantheus	$100.91 0.0%	$104.24	$49.67 ▼ $111.86	$6.59B	-0.03	1.94 million shs	895,559 shs
TRLV Trulieve Cannabis	$9.48 -1.8%	$8.94	$4.62 ▼ $13.28	$1.86B	N/A	786,242 shs	753,389 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	+1.49%	+3.02%	+3.19%	+55.97%	+94.92%
BLTE Belite Bio	+0.25%	-2.42%	+8.75%	+16.83%	+144.95%
LNTH Lantheus	-0.04%	-0.07%	-6.21%	+8.63%	+86.25%
TRLV Trulieve Cannabis	-1.17%	+5.10%	+7.87%	+947,999,900.00%	+947,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$18.42 +1.5%	$17.33	$9.20 ▼ $19.26	$5.80B	1.27	1.87 million shs	1.62 million shs
BLTE Belite Bio	$163.21 +0.3%	$152.97	$60.00 ▼ $200.00	$6.53B	-1.22	186,143 shs	180,493 shs
LNTH Lantheus	$100.91 0.0%	$104.24	$49.67 ▼ $111.86	$6.59B	-0.03	1.94 million shs	895,559 shs
TRLV Trulieve Cannabis	$9.48 -1.8%	$8.94	$4.62 ▼ $13.28	$1.86B	N/A	786,242 shs	753,389 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	+1.49%	+3.02%	+3.19%	+55.97%	+94.92%
BLTE Belite Bio	+0.25%	-2.42%	+8.75%	+16.83%	+144.95%
LNTH Lantheus	-0.04%	-0.07%	-6.21%	+8.63%	+86.25%
TRLV Trulieve Cannabis	-1.17%	+5.10%	+7.87%	+947,999,900.00%	+947,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	3.00	Buy	$17.67	-4.09% Downside
BLTE Belite Bio	2.88	Moderate Buy	$205.80	26.10% Upside
LNTH Lantheus	2.29	Hold	$108.11	7.14% Upside
TRLV Trulieve Cannabis	2.00	Hold	$15.00	58.23% Upside

Current Analyst Ratings Breakdown

Latest TRLV, BLTE, LNTH, and AMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/14/2026	BLTE Belite Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$201.00 ➝ $206.00
8/14/2026	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$220.00
8/13/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/12/2026	AMRX Amneal Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/12/2026	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$266.00 ➝ $270.00
8/12/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$200.00 ➝ $214.00
8/7/2026	AMRX Amneal Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2026	TRLV Trulieve Cannabis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$15.00
8/4/2026	LNTH Lantheus	CJS Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.02B	1.95	$1.59 per share	11.62	($0.23) per share	-80.09
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
LNTH Lantheus	$1.54B	4.27	$6.38 per share	15.81	$16.43 per share	6.14
TRLV Trulieve Cannabis	$1.14B	1.60	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	37.59	16.30	N/A	5.05%	-584.46%	7.78%	N/A
BLTE Belite Bio	-$77.61M	-$2.73	N/A	N/A	N/A	N/A	-11.84%	-11.62%	N/A
LNTH Lantheus	$233.56M	$4.14	24.37	18.76	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
TRLV Trulieve Cannabis	N/A	N/A	N/A	22.05	N/A	N/A	N/A	N/A	N/A

Latest TRLV, BLTE, LNTH, and AMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/7/2026	Q2 2026	TRLV Trulieve Cannabis	$0.06	$0.11	+$0.05	-$2.10	$268.82 million	$271.00 million
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
BLTE Belite Bio	N/A	33.56	33.56
LNTH Lantheus	0.43	3.06	2.89
TRLV Trulieve Cannabis	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
BLTE Belite Bio	0.53%
LNTH Lantheus	99.06%
TRLV Trulieve Cannabis	N/A

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
BLTE Belite Bio	13.29%
LNTH Lantheus	1.70%
TRLV Trulieve Cannabis	3.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
BLTE Belite Bio	10	40.08 million	34.76 million	Not Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
TRLV Trulieve Cannabis	5,000	192.31 million	185.27 million	N/A

TRLV, BLTE, LNTH, and AMRX Headlines

Recent News About These Companies

Trulieve Cannabis (NYSE:TRLV) Trading Up 8.3% - Here's What Happened

August 13, 2026 | marketbeat.com

3 Marijuana Stocks For Investors To Consider

August 12, 2026 | marijuanastocks.comM

Trulieve Completes Redomicile from British Columbia to Delaware

August 11, 2026 | prnewswire.com

Trulieve Cannabis' (TRLV) Overweight Rating Reiterated at Cantor Fitzgerald

August 10, 2026 | americanbankingnews.com

Trulieve Cannabis Q2 Earnings Call Highlights

August 9, 2026 | marketbeat.com

Trulieve Cannabis (TRLV) Reports Steeper Losses And Lower Sales, Is The Valuation Discount Justified?

August 8, 2026 | uk.finance.yahoo.com

Trulieve Cannabis (NYSE:TRLV) Rating Lowered to "Hold" at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Trulieve Cannabis (NYSE:TRLV) Cut to Hold at Wall Street Zen

August 8, 2026 | marketbeat.com

Trulieve Cannabis (NYSE:TRLV) Releases Earnings Results, Beats Estimates By $0.05 EPS

August 7, 2026 | marketbeat.com

Trulieve Cannabis (NYSE:TRLV) Update: Key Signals to Watch

August 7, 2026 | kalkinemedia.comK

Trulieve Cannabis Corp. 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

Trulieve Cannabis (NYSE:TRLV) Given Overweight Rating at Cantor Fitzgerald

August 7, 2026 | marketbeat.com

Trulieve: Q2 Earnings Snapshot

August 7, 2026 | chron.com

Trulieve Reports Second Quarter 2026 Results

August 7, 2026 | prnewswire.com

Der aktuelle Kurs der Trulieve Cannabis Corp Aktie beträgt 8,9600.

August 5, 2026 | de.investing.com

Trulieve Announces August 2026 Event Participation

August 5, 2026 | prnewswire.com

Trulieve Cannabis Corp. (NYSE:TRLV) Sees Large Growth in Short Interest

July 28, 2026 | marketbeat.com

Cantor Fitzgerald Begins Coverage on Trulieve Cannabis (NYSE:TRLV)

July 20, 2026 | marketbeat.com

Trulieve to Open Medical Cannabis Dispensary in Marco Island, Florida

July 16, 2026 | prnewswire.com

Why Is Trulieve (NYSE:TRLV) Expanding Its NYSE Presence?

July 13, 2026 | kalkinemedia.comK

Two marijuana MSOs named among ‘America’s Best Companies’

July 10, 2026 | mjbizdaily.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV, BLTE, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$18.42 +0.27 (+1.49%)

As of 08/17/2026 04:00 PM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Belite Bio NASDAQ:BLTE

$163.21 +0.41 (+0.25%)

As of 08/17/2026 04:00 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus NASDAQ:LNTH

$100.91 -0.04 (-0.04%)

As of 08/17/2026 04:00 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Trulieve Cannabis NYSE:TRLV

$9.48 -0.17 (-1.76%)

As of 08/17/2026 03:58 PM Eastern

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRLV, BLTE, LNTH, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRLV, BLTE, LNTH, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRLV, BLTE, LNTH, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV, BLTE, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRLV, BLTE, LNTH, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRLV, BLTE, LNTH, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRLV, BLTE, LNTH, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV, BLTE, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools